Real-World check: new combo therapy for tough uterine cancer under the microscope

NCT ID NCT06890273

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 32 times

Summary

This study tracks 150 women with advanced or returning endometrial cancer to see how well a first treatment of chemotherapy plus durvalumab works, followed by maintenance durvalumab (with or without olaparib). It collects real-world data from German hospitals to measure how long patients go before needing another treatment. The goal is to understand effectiveness and side effects outside of a controlled trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Amberg, Germany
Research Site
RECRUITING

Bad Nauheim, Germany
Research Site
RECRUITING

Bautzen, Germany
Research Site
RECRUITING

Berlin, Germany
Research Site
RECRUITING

Bielefeld, Germany
Research Site
RECRUITING

Borna, Germany
Research Site
RECRUITING

Bottrop, Germany
Research Site
RECRUITING

Brandenburg an der Havel, Germany
Research Site
RECRUITING

Braunschweig, Germany
Research Site
RECRUITING

Cologne, Germany
Research Site
RECRUITING

Dessau, Germany
Research Site
RECRUITING

Dresden, Germany
Research Site
RECRUITING

Ebersberg, Germany
Research Site
RECRUITING

Essen, Germany
Research Site
RECRUITING

Goslar, Germany
Research Site
RECRUITING

Greifswald, Germany
Research Site
RECRUITING

Gütersloh, Germany
Research Site
RECRUITING

Heilbronn, Germany
Research Site
RECRUITING

Homburg, Germany
Research Site
RECRUITING

Hösbach, Germany
Research Site
RECRUITING

Krefeld, Germany
Research Site
RECRUITING

Kulmbach, Germany
Research Site
RECRUITING

Landshut, Germany
Research Site
RECRUITING

Leipzig, Germany
Research Site
RECRUITING

Limburg, Germany
Research Site
RECRUITING

Lüneburg, Germany
Research Site
RECRUITING

Magdeburg, Germany
Research Site
RECRUITING

Mainz, Germany
Research Site
RECRUITING

München, Germany
Research Site
RECRUITING

Neuss, Germany
Research Site
RECRUITING

Nuremberg, Germany
Research Site
RECRUITING

Plauen, Germany
Research Site
RECRUITING

Rotenburg (Wümme), Germany
Research Site
RECRUITING

Siegen, Germany
Research Site
RECRUITING

Solingen, Germany
Research Site
RECRUITING

Torgau, Germany
Research Site
RECRUITING

Traunstein, Germany
Research Site
RECRUITING

Unna, Germany
Research Site
RECRUITING

Weningerode, Germany
Research Site
RECRUITING

Winnenden, Germany
Research Site
RECRUITING

Witten, Germany
Research Site
RECRUITING

Worms, Germany

Conditions

The condition(s) this trial relates to.

endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL CANCER ENDOMETRIAL CANCER